Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2010-04-23 | Stephen R. Davis has served as a member of our Board since February 2010. Mr. Davis was Chief Executive Officer of Neurogen Corporation, a biotechnology company that develops products for the treatment of psychiatric and neurological disorders, from February 2008 through December 2009, when Neurogen Corporation was acquired by Ligand Pharmaceuticals Incorporated. Mr. Davis is the Board of Directors’ designee of Baker Brothers Investments. |
| 2013-08-26 | Stephen R. Davis, Executive Vice President and Chief Operating Officer, Director, includes 47,946 shares of common stock and 1,483,677 shares underlying stock options exercisable within 60 days of July 31, 2013. |
| 2014-04-24 | Stephen R. Davis has served as a member of our Board since June 2012. Mr. Davis was appointed Executive Vice President and Chief Operating Officer in May 2013. Mr. Davis was Executive Vice President and Chief Operating Officer of Ardea Biosciences, Inc. from April 2010 until December 2012. Compensation that Mr. Davis received as director prior to being Named Executive Officer is fully reflected in the Summary Compensation Table. Summary Compensation Table shows total compensation for Mr. Davis in 2013 as $4,162,387. |
Data sourced from SEC filings. Last updated: 2025-10-12